サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179951

にきび治療薬の世界市場-2023-2030

Global Acne Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
にきび治療薬の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

にきび治療薬の世界市場規模は、予測期間（2023-2030年）にCAGR4.7％で成長すると予測されています。

思春期は、毛母細胞の炎症性疾患であるにきびが最も多く発生する時期です。オープン（黒色）およびクローズ（白色）の面ぽう、炎症性丘疹、膿疱、結節、嚢胞が特徴的な病変で、瘢痕や色素性変化を引き起こすことがあります。にきびの多因子病態には、毛包の角化異常、高アンドロゲン主義による皮脂分泌の増加、アクネ菌の増殖、炎症が含まれます。

市場力学

世界のにきび治療薬市場を牽引する主な要因は、より迅速な治療とより良い結果に対する要望の高まり、にきび関連疾患の発生率の増加、抗生物質やレチノイドなどの様々なにきび治療製品の使用、そしてこの疾患に対する認知度の高まりがさらに市場に影響を与えています。

より迅速な治療とより良い結果に対する要望の高まりが、市場の成長を促進すると予想されます。

患者がより迅速な治療と効果的な結果を期待する中、レーザーのような機器による治療のニーズが高まると予想されます。レーザー処置は、顔の毛の増加や色素異常などの問題の再発とその将来の発生を防止します。さらに、患者は、他の形態よりも不快感が少ないので、レーザー治療に簡単に適応する可能性があります。例えば、医師は、局所抗生物質とレチノイドのペアリングなど、永久ににきびの発症を減らすために組み合わせ薬を活用することをお勧めします。

皮膚科タイムズ、2022は、皮脂腺をターゲットとし、軽度から重度のために米国食品医薬品局（FDA）によって認定された最初のデバイスであるAviClearレーザーの最近のクリアランスは、にきびのエネルギーベースの治療を強化していることを報告します。電気熱分解は、皮脂腺を選択的に破壊することで、安全かつ効率的ににきびを治療する方法であることが、研究により明らかにされています。63人の患者を含む無作為化比較研究によると、4週間間隔で3回のエレクトロサーモリシス治療を受けた治療グループは、12週目に炎症性にきび病変が著しく減少したと、独立した2人の医師によって判定されました。このような研究は、にきびの治療にエネルギーを利用した機器を使用する道を開きました。「最近の機器によるにきび治療では、皮脂に特異的な波長が用いられています。

にきび治療薬に伴う副作用が市場成長の妨げになることが予想されます。

また、患者が他の選択肢に切り替えることや、すでに利用可能な治療法の副作用が、市場の収益成長鈍化の要因になる可能性があります。

COVID-19の影響分析

COVID-19の大流行は中国に端を発し、世界中に広がっています。ほぼすべての国がこのパンデミックの影響を受けています。ほとんどの国がパンデミックと戦うためにロックダウンを実施したため、にきび治療薬市場に影響を及ぼしています。パンデミックは、産業の広い範囲にわたって経済拡大を減速させました。この感染症は、世界中のヘルスケアシステムに負担をかけ、多くの皮膚科クリニックが安全性の懸念から一般人の受診が不可能になっています。

新型コロナウイルス感染症患者の治療と隔離のために、いくつかの病院や診療所はパンデミック承認済みの病院構造を用いてCOVID-19センターに改修されました。また、ロックダウンにより、多くの患者が薬局や皮膚科医院に処方箋を受け取りに行くことができないです。遠隔医療は、現代の環境下でにきび患者に重要な皮膚科サービスを提供するための有効かつ効果的な方法となっています。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • より迅速な治療とより良い結果への欲求の高まり
      • にきび関連疾患の発生率とにきび治療製品の使用量の増加
    • 抑制要因
      • にきび治療薬に関連する副作用
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 タイプ別

  • 有病性
  • 炎症性
  • シスチック
  • 術後・創傷

第8章 治療クラス別

  • レチノイド
  • 抗生物質
  • ホルモン剤
  • 併用療法
  • その他

第9章 投与経路別

  • 外用剤
  • 経口
  • 注射剤

第10章 流通経路別

  • 小売店
  • 薬局・薬店
  • オンラインストア

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第12章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第13章 企業プロファイル

  • Sun Pharmaceutical Industries, Inc
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Allergan Plc
  • Galderma S.A
  • Johnson & Johnson
  • Reckitt Benckiser Group
  • Guthy-Renker
  • Stiefel Laboratories
  • Valeant Pharmaceuticals
  • Teva Pharmaceuticals
  • Cutera Inc.

第14章 にきび治療薬の世界市場-DataM

目次
Product Code: DMPH3600

Market Overview

The global acne therapeutics market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.7% during the forecast period (2023-2030).

Adolescence is the most common time for acne, an inflammatory condition of the pilosebaceous units. Open (black) and closed (white) comedones, inflammatory papules, pustules, nodules, and cysts are the distinctive lesions that may result in scarring and pigmentary alterations. Acne's multifactorial pathophysiology includes aberrant follicular keratinization, increased sebum production by hyperandrogenism, Propionibacterium acnes growth, and inflammation.

Market Dynamics

The major factors driving the global acne therapeutics market are the increasing desire for quicker treatment and better results, increasing incidence of acne-related conditions and the usage of various acne treatment products, including antibiotics and retinoids, and the growing awareness of the condition further influence the market.

An increasing desire for quicker treatment and better results is expected to drive the market's growth.

As patients expect more expedient therapies and effective outcomes, the need for equipment-based therapies like lasers is anticipated to rise. Laser procedures prevent the recurrence of issues, including increased facial hair growth and pigmentation abnormalities and their future occurrence. Additionally, patients might adapt more easily to laser treatments because they are less uncomfortable than other forms. For instance, doctors advise utilizing combination medication to permanently reduce the development of acne, such as pairing a topical antibiotic with a retinoid.

Dermatology Times, 2022 reports the recent clearance of the AviClear laser, which targets sebaceous glands and is the first device certified by the US Food and Drug Administration (FDA) for mild-to-severe, has enhanced the energy-based therapy of acne. Studies have shown that electro thermolysis is a secure and efficient way of treating acne by selectively destroying sebaceous glands. According to a randomized, controlled research including 63 patients, the treatment group, which underwent three electro thermolysis treatments spaced four weeks apart, experienced a significant decrease in inflammatory acne lesions at week 12, as determined by two independent physicians. Such investigations paved the way for using energy-based devices to treat acne. "The most recent developments in device-based acne treatment use wavelengths unique to sebum.

Side effects associated with acne therapeutics are expected to hamper the market's growth.

Additionally, patients switching to other options and the adverse effects of the already accessible treatments may be contributing factors to the market's slow revenue growth.

COVID-19 Impact Analysis

The COVID-19 outbreak originated in China and has spread far over the world. Nearly all countries are affected by the pandemic. As most nations implemented lockdowns to battle the pandemic, this affects the acne therapeutics market. The pandemic has slowed down economic expansion across a wide range of industries. The covid has put a strain on healthcare systems worldwide, and many dermatology clinics are no longer accessible to the public due to safety concerns.

For the treatment and isolation of patients with the covid infection, several hospitals and clinics have been modified into COVID-19 centers using pandemic-approved hospital structures. The lockdown also prevents many patients from getting to pharmacies and dermatologist offices to pick up their prescriptions. Telemedicine has become a viable and effective way to deliver crucial dermatological services to acne patients in the contemporary environment.

Segment Analysis

The retinoid segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The market for acne treatments is anticipated to be dominated by the retinoid segment. The demand for retinoid creams and gels has surged since they successfully treat or prevent mild to moderate acne. After a successful treatment, they can also be used as maintenance therapy to keep the skin clear. Additionally, market participants constantly introduce brand-new and generic retinoids to acquire a competitive edge in the market.

For instance, in March 2022, Twyneo, a cream with tretinoin 0.1% and benzoyl peroxide 3.0%, was approved by the FDA for the topical treatment of acne vulgaris in patients 9 years of age and older. Twyneo is a fixed-dose mixture of the topical antibiotic benzoyl peroxide and the retinoid tretinoin 0.1%. To include the two active ingredients in the cream, Twyneo's formulation uses silica core-shell structures to independently microencapsulate the tretinoin and benzoyl peroxide crystals. The increasing number of retinoid product launches will result in more adoption because of their effectiveness in treating acne, which is anticipated to propel the expansion of this market.

Throughout the projection period, increased research and development for discontinued acne therapies will also benefit expanding this market. For instance, in April 2021, Ortho Dermatologics, a division of Bausch Health specializing in prescription dermatology, released encouraging topline results from its second Phase III trial for IDP-126, a three-compound combination gel tested on 193 people with acne vulgaris. The results showed reductions in both inflammatory and non-inflammatory lesions at week 12 in both conditions. Adapalene, retinol, and the antimicrobial benzoyl peroxide are all included in IDP-126. Such retinoid-related research is anticipated to help the segment's growth by increasing sales and manufacturing of related items.

Global Acne Therapeutics Market- Geographical Analysis

North America holds the largest market share in the global acne therapeutics market.

North America dominates the global acne therapeutics market primarily due to its large population, excellent medical infrastructure, and high-income levels. The key drivers propelling the growth of the acne therapeutics market in North America are the rising prevalence of acne in the region, acquisitions, and recent product introductions. In order to compete with those already on the market, a significant number of key market players are developing new products and technologies, while others are acquiring or partnering with other companies that are in high demand in the acne therapeutics market.

For instance, in December 2021, Sanofi announced an agreement to buy Origimm Biotechnology GmbH, a privately held biotechnology business based in Austria that specializes in identifying pathogenic skin microbiome components and antigens from bacteria that cause skin conditions, including acne. By making this acquisition, Sanofi is continuing to implement its global Play to Win strategy, look for growth possibilities, and develop a portfolio of vaccines that leads the market.

For instance, in November 2021, the US market for Winlevi cream, used to treat acne in individuals 12 years of age and older was announced by Sun Pharmaceutical Industries. Winlevi, a topical androgen receptor inhibitor that is the first of its kind, received FDA approval in August 2020. According to a statement from Sun Pharma, Winlevi is the first FDA-approved acne medication with the first-in-class mechanism of action in nearly 40 years. It prevents the effects of androgen receptors in sebaceous gland cells, which are responsible for creating sebum (oil) and irritation in the skin. It is appropriate for both genders. Therefore, it is anticipated that the market under study in the North American area will be driven by regular product launches and research and development initiatives undergoing the creation of novel acne therapies.

Competitive Landscape

The acne therapeutics market is moderately competitive with local and global companies' presence Sun Pharmaceutical Industries, Inc, Allergan Plc, Galderma S.A, Johnson & Johnson, Reckitt Benckiser Group, Guthy-Renker, Stiefel Laboratories, Valeant Pharmaceuticals

Teva Pharmaceuticals, Cutera Inc, and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in March 2022, The U.S. Food and Drug Administration cleared AviClear, the first and only energy-based device to do so for the treatment of mild, moderate, and severe acne. CUTERA, INC. ("Cutera" or the "Company"), a leading developer of dermatology solutions, released the news.

Sun Pharmaceutical Industries, Inc.

Overview: An extensive selection of pharmaceutical formulations, including branded generics and generic medications, are offered by Sun Pharmaceutical Industries Ltd. (Sun Pharma), a specialty pharmaceutical company. Products for the treatment of psychiatric, neurological, nephrological, gastroenterological, Orthopedic, and ophthalmologic diseases and disorders, as well as cardiac problems, are part of the company's portfolio.

Product Portfolio:

ABSORICA LD (isotretinoin): Under fed conditions, ABSORICA LD 32 mg is bioequivalent to ABSORICA 40 mg. Additionally, ABSORICA LD has a similar safety profile while providing twice the absorption of ABSORICA in a fasting condition. ABSORICA LD is not interchangeable with any other isotretinoin that is currently on the market and offers maximum isotretinoin absorption at a 20% lower dose.

The global acne therapeutics market report would provide access to approx.: 45+ market data tables, 40+ figures, and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing desire for quicker treatment and better results
      • 4.1.1.2. Increasing incidence of acne-related conditions and the usage of various acne treatment products
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with acne therapeutics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Comedonal
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Inflammatory
  • 7.4. Cystic
  • 7.5. Postsurgical/wound

8. By Therapeutic Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 8.1.2. Market Attractiveness Index, By Therapeutic Class
  • 8.2. Retinoid
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Antibiotic
  • 8.4. Hormonal Agent
  • 8.5. Combination
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Topical
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Oral
  • 9.4. Injectable

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Retail Store
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Pharmacy & Drug Store
  • 10.4. Online Stores

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Class
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Sun Pharmaceutical Industries, Inc
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Allergan Plc
  • 13.3. Galderma S.A
  • 13.4. Johnson & Johnson
  • 13.5. Reckitt Benckiser Group
  • 13.6. Guthy-Renker
  • 13.7. Stiefel Laboratories
  • 13.8. Valeant Pharmaceuticals
  • 13.9. Teva Pharmaceuticals
  • 13.10. Cutera Inc.

LIST NOT EXHAUSTIVE

14. Global Acne Therapeutics Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us